Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model

Critical Care Medicine

Volumn 35, Issue 6, 2007, Pages 1560-1567

  Sherer, Kevin ^a   Li, Yan ^a   Cui, Xizhong ^a   Li, Xuemei ^a   Subramanian, Mani ^c   Laird, Michael W ^c,d   Moayeri, Mahtab ^b   Leppla, Stephen H ^b   Fitz, Yvonne ^a   Su, Junwu ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GENENTECH INC   (United States)

Author keywords

Bacillus anthracis; Fluids; Lethal toxin; Rodent; Sepsis; Treatment

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5H3; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BACILLUS ANTHRACIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ESCHERICHIA COLI; EXPERIMENTAL STUDY; FLUID THERAPY; HAZARD RATIO; LABORATORY; MALE; MEDICAL RESEARCH; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROVOCATION TEST; RAT; SHOCK; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; SURVIVAL;

EID: 34249275349     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000266535.95770.A2     Document Type: Article

References (38)

1. Swartz MN: Recognition and management of anthrax - An update. N Engl J Med 2001;345:1621-1626
2. Inglesby TV, O'Toole T, Henderson DA, et al: Anthrax as a biological weapon, 2002: Updated recommendations for management. JAMA 2002; 287:2236-2252
3. Holty JE, Bravata DM, Liu H, et al: Systematic review: A century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270-280
4. Jernigan JA, Stephens DS, Ashford DA, et al: Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933-944
5. Barakat LA, Quentzel HL, Jernigan JA, et al: Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002; 287:863-868
6. Friedman G, Silva E, Vincent JL: Has the mortality of septic shock changed with time? Crit Care Med 1998; 26:2078-2086
7. Earls JP, Cerva D, Berman E, et al: Inhalational anthrax after bioterrorism exposure: Spectrum of imaging findings in two surviving patients. Radiology 2001; 222:305-312
8. Abramova FA, Grinberg LM, Yampolskaya OV, et al: Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA 1993; 90:2291-2294
9. Leppla SH: Anthrax toxin. In: Bacterial Proteins. Aktories K, Just I (Eds). New York, Springer, 2000, pp 445-472
10. Sherer K, Li Y, Cui X, et al: Lethal and edema toxins in the pathogenesis of Bacillus anthracis shock: Implications for therapy. Am J Respir Crit Care Med 2007; 175:211-221
11. Ezzell JW, Ivins BE, Leppla SH: Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect Immun 1984; 45:761-767
12. Molnar DM, Altenbern RA: Alterations in the biological activity of protective antigen of Bacillus anthracis toxin. Proc Soc Exp Biol Med 1963; 114:294-297
13. Pezard C, Berche P, Mock M: Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun 1991; 59:3472-3477
14. Cui X, Moayeri M, Choi GH, et al: Late treatment with a protective antigen derived monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis 2005; 191:422-434
15. Mohamed N, Clagett M, Li J, et al: A high-affinity monoclonal antibody to the anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 2005; 73:795-802
16. Beeb E, Zhong J, Clagett M, et al: Protection against inhalation anthrax-induced lethality by a human monoclonal antibody to protective antigen in rabbits and cynomolgus monkeys. Abstr B-331. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC, American Society for Microbiology, 2003, p 47
17. Duesbery NS, Webb CP, Leppla SH, et al: Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998; 280:734-737
18. Vitale G, Pellizzari R, Recchi C, et al: Anthrax lethal factor cleaves the N-terminus of MAPKKS and induces tyrosine/threonine phosphorylation of MAPKS in cultured macrophages. J Appl Microbiol 1999; 87:288
19. Ho DT, Bardwell AJ, Abdollahi M, et al: A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J Biol Chem 2003; 278:32662-32672
20. Bardwell AJ, Abdollahi M, Bardwell L: Anthrax lethal factor-cleavage products of MAPK kinases exhibit reduced binding to their cognate MAPKs. Biochem J 2004; 378:569-577
21. Cui X, Moayeri M, Li Y, et al: Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol Regul Integr Comp Physiol 2004; 286:R699-R709
22. Cui X, Li Y, Li X, et al: Sublethal doses of Bacillus anthracis lethal toxin inhibit inflammation with lipopolysaccharide and Escherichia coli challenge but have opposite effects on survival. J Infect Dis 2006; 193:829-840
23. Kirby JE: Anthrax toxin induces human endothelial cell apoptosis. Infect Immun 2004; 72:430-439
24. Warfel JM, Steele AD, D'Agnillo F: Anthrax lethal toxin induces endothelial barrier dysfunction. Am J Pathol 2005; 166:1871-1881
25. Gozes Y, Moayeri M, Wiggins JF, et al: Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice. Infect Immun 2006; 74:1266-1272
26. Lundblad R, Giercksky K: Effect of volume support, antibiotic therapy, and monoclonal antiendotoxin antibodies on mortality rate and blood concentrations of endothelin and other mediators in fulminant intra-abdominal sepsis in rats. Crit Care Med 1995; 23:1382-1390
27. Zhong J, Rubin LJ, Parker JL, et al: Cardiodynamic response to Escherichia coli endotoxemia: Effects of fluid resuscitation. Shock 1994; 2:203-209
28. Anning PB, Finney SJ, Singh S, et al: Fluids reverse the early lipopolysaccharide-induced albumin leakage in rodent mesenteric venules. Intensive Care Med 2004; 30:1944-1949
29. Smith EF III, Slivjak MJ, Egan JW, et al: Fluid resuscitation improves survival of endotoxemic or septicemic rats: Possible contribution of tumor necrosis factor. Pharmacology 1993; 46:254-267
30. Magder S, Vanelli G: Circuit factors in the high cardiac output of sepsis. J Crit Care 1996; 11:155-166
31. Somell A, Sollevi A, Suneson A, et al: Beneficial effects of hypertonic saline/dextran on early survival in porcine endotoxin shock. Acta Anaesthesiol Scand 2005; 49:1124-1134
32. Eichacker PQ, Parent C, Kalil A, et al: Risk and efficacy of anti-inflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166:1197-1205
33. Park S, Leppla SH: Optimized production and purification of Bacillus anthracis lethal factor. Protein Expr Purif 2000; 18:293-302
34. Ramirez DM, Leppla SH, Schneerson R, et al: Production, recovery, and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis. J Ind Microbiol Biotechnol 2002; 28:232-8
35. Kalil AC, Sevransky JE, Myers DE, et al: Preclinical trial of L-arginine monotherapy alone or with N-acetylcysteine in septic shock. Crit Care Med 2006; 34:2719-2728
36. Lucey D: Anthrax. In: Principles and Practice of Infectious Diseases. Mandell GL, Bennett JE, Dolin R (Eds). New York, Elsevier, 2005, pp 3618-3624
37. Popov SG, Popova TG, Hopkins S, et al: Effective antiprotease-antibiotic treatment of experimental anthrax. BMC Infect Dis 2005; 5:25
38. Shannon JG, Ross CL, Koehler TM, et al: Characterization of anthrolysin O, the Bacillus anthracis cholesterol-dependent cytolysin. Infect Immun 2003; 71:3183-3189